Yeztugo® (lenacapavir) – New drug approval
June 18, 2025 - Gilead announced the FDA approval of Yeztugo (lenacapavir), for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition.
Download PDF
